Skip to main content

Table 5 Comparison of antithrombotic therapy between the pre-campaign and campaign periods

From: Impact of care coordination on oral anticoagulant therapy among patients with atrial fibrillation in routine clinical practice in Japan: a prospective, observational study

  Pre-campaign period
N = 86
Campaign period
N = 90
Antithrombotic therapy 60 (69.8) 70 (77.8)
 Oral anticoagulant agents 52 (60.5) 62 (68.9)
  Warfarin 11 (21.2) 11 (17.7)
  DOACs 41 (78.8) 51 (82.3)
 Antiplatelet agents 12 (14.0) 10 (11.1)
CHADS2 score low (score, 0) N = 4 N = 6
 Oral anticoagulant agents 4 (100.0) 2 (33.3)
  Warfarin 0 (0.0) 0 (0.0)
  DOACs 4 (100.0) 2 (100.0)
CHADS2 score Intermediate (score, 1) N = 13 N = 10
 Oral anticoagulant agents 7 (53.8) 9 (90.0)
  Warfarin 1 (14.3) 3 (33.3)
  DOACs 6 (85.7) 6 (66.7)
CHADS2 score high (score, ≥2) N = 69 N = 74
 Oral anticoagulant agents 41 (59.4) 51 (68.9)
  Warfarin 10 (24.4) 8 (15.7)
  DOACs 31 (75.6) 43 (84.3)
OAC therapy based on JCS 2013 guidelines 48 (55.8) 64 (71.1)
  1. Data are n (%)
  2. Abbreviations: JCS 2013 Japanese guidelines for pharmacotherapy of atrial fibrillation, DOACs Direct oral anticoagulants